首页 News 正文

According to AI News, on December 9th, Tianjing Biotechnology and Jichuan Pharmaceutical jointly announced that the biological product marketing application (BLA) for the treatment of children with growth hormone deficiency (PGHD) with Yitan long-acting recombinant human growth hormone injection (hereinafter referred to as "Yitan long-acting growth hormone") has been approved by NMPA.
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

六月清晨搅 注册会员
  • 粉丝

    0

  • 关注

    0

  • 主题

    30